Platelet News and Research

RSS

New drug might effectively prevent clot-related strokes in patients with AF

For patients with a type of irregular heart beat called atrial fibrillation (AF), a new anti-clotting drug might be better at preventing clot-related strokes while minimizing the risk of causing a bleeding stroke.

3 Feb 2012

Progenitor cells have potential to develop into RBCs

A study of the cells that respond to crises in the blood system has yielded a few surprises, redrawing the 'map' of how blood cells are made in the body.

1 Feb 2012

Haemonetics third quarter net income decreases 8% to $18.3M

Haemonetics Corporation today reported third quarter 2012 GAAP net revenue of $191.2 million, up 8%, net income of $18.3 million, down 8%, and diluted earnings per share of $0.72, down 7%.

31 Jan 2012

Technoclone, Roche enter strategic alliance to co-develop coagulation assays

Roche announced today that it has entered into a strategic alliance with Technoclone, a reagent specialist in thrombosis and cardiovascular diagnostics based in Vienna, Austria, to co-develop a complete range of coagulation assays.

From Roche Sequencing and Life Science 27 Jan 2012

Creighton researcher to study role of adult stem cells in repairing damaged coronary arteries

A Creighton University School of Medicine researcher has received a $3.3 million, five-year grant from the National Institutes of Health to study what role adult stem cells might play in repairing damaged coronary arteries, a complication that often occurs in patients after they undergo angioplasty and stenting.

24 Jan 2012

Platelet receptor could help with diseases that impact RBCs

A receptor found on blood platelets whose importance as a potential pharmaceutical target has long been questioned may in fact be fruitful in drug testing, according to new research from Michigan State University chemists.

20 Jan 2012

Cangrelor allows stent patients to be 'bridged' to cardiac surgery

New findings from a research study led by physicians at Scripps Health reveal that the investigational drug cangrelor has the unique properties of achieving very fast blood thinning effects when needed to protect from heart attacks, but also dissipates rapidly so patients can undergo surgery without the excessive bleeding often associated with blood thinning medications.

18 Jan 2012

Ethanol, nonalcoholic compounds in red wine may reduce risk of vascular disease

Observational epidemiologic studies relating wine and alcohol to health all suffer from the fact that they, of necessity, compare people who prefer certain beverages, but not the beverages themselves. While there have been many intervention trials in animals, randomized trials in humans are less common. Randomized crossover trials, in which each subject receives all interventions in sequence, can be especially important as they tend to avoid baseline differences among subjects and can detect effects of different interventions with smaller numbers of subjects.

18 Jan 2012

Combination of tenotomy and PRP injections can treat tendon disorders

Many athletes know the frustration of being sidelined by tendon disorders, like Achilles tendinitis and tennis elbow. In recent years, doctors have begun treating overused tendons with regenerative therapies that jump-start the body's own healing process. One technique, a tenotomy, uses repeated needlesticks to break up scar tissue in the tendon, prompting the body's own cells to begin the rebuilding process.

18 Jan 2012

Arthrex to market ThermoGenesis Res-Q 60 System technology for PRP and BMC preparation

ThermoGenesis Corp., a leading supplier of innovative products and services that process and store human cell concentrates, said today it has entered into a five year collaboration with Arthrex, Inc., under which Arthrex will market ThermoGenesis' Res-Q 60 (Res-Q) System technology for use in the preparation of autologous Platelet Rich Plasma (PRP) and Bone Marrow Concentrate (BMC).

11 Jan 2012

Meta-analysis does not find significant association between CYP2C19 genotype and cardiovascular events

Although the U.S. Food and Drug Administration (FDA) has recommended that a certain type of genetic testing (for the genotype CYP2C19) be considered before prescribing the drug clopidogrel to identify individuals who may be less responsive to the medication, a review and analysis of previous studies did not find an overall significant association between the CYP2C19 genotype and cardiovascular events.

28 Dec 2011

Study evaluates use of leukocyte and platelet-rich fibrin biomaterial in heart patients

Cardiac patients that take anticoagulant medications and need a tooth extraction face an increased risk of bleeding that must be addressed by the treating clinician. Therefore, a protocol for heart patients is needed that will avoid significant bleeding after dental extractions without suspending anticoagulant therapy.

15 Dec 2011

Novel prognostic model for patients with treatment-related MDS

A large-scale analysis of patients whose myelodysplastic syndrome is related to earlier cancer treatment overturns the notion that all of them have a poor prognosis, researchers from The University of Texas MD Anderson Cancer Center report at the 53rd Annual Meeting of the American Society of Hematology.

15 Dec 2011

S*BIO announces results from pacritinib Phase 2 study on myelofibrosis

S*BIO Pte Ltd today announced that results from a Phase 2 study demonstrated that its JAK2 inhibitor pacritinib (SB1518) effectively reduced splenomegaly in myelofibrosis (MF) patients, with minimal impact on existing cytopenias providing an important therapeutic niche in the treatment of MF. Results were presented at the 53rd ASH Annual Meeting and Exposition in San Diego.

13 Dec 2011

Combination of bortezomib and panobinostat shows promise against advanced MM

When the targeted drug bortezomib stops working in patients with advanced multiple myeloma, the patients survive only an average of five months longer. But a phase 2 clinical trial has shown that pairing bortezomib with an experimental drug, panobinostat, may be a promising new treatment for such patients, Dana-Farber Cancer Institute researchers say.

13 Dec 2011

Research examines novel treatment techniques for hemophilia B, VTE

Bleeding and clotting disorders affect a large number of patients annually and, while accurate diagnosis is important, timely and effective treatment for these disorders is key, as they have the potential to quickly become life-threatening. Research examining novel treatment techniques for bleeding and clotting disorders will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

FDA approves changes to REMS for Nplate and Promacta

The approval of changes to the Risk Evaluation and Mitigation Strategies (REMS) for both Nplate (romiplostim) and Promacta (eltrombopag) was announced by the U.S. Food and Drug Administration.

7 Dec 2011

Roche signs agreement to acquire Verum Diagnostica

Roche announced today that it has signed an agreement under which it will acquire 100 percent of Verum Diagnostica GmbH, based in Munich, Germany.

From Roche Sequencing and Life Science 6 Dec 2011

American Plasma Users Coalition awarded $40,000 advocacy grant from CSL Behring

CSL Behring announced today that it has awarded a $40,000 advocacy grant to the American Plasma Users Coalition (A-PLUS) through its Local Empowerment for Advocacy Development (LEAD) program. LEAD grants support the grassroots advocacy efforts of organizations that help people who use plasma-derived or recombinant therapies to manage rare and serious medical disorders.

3 Dec 2011

ASH recognizes abstract presenters at 53rd annual meeting in San Diego

The American Society of Hematology (ASH) recognizes the following abstract presenters at the 53rd ASH annual meeting in San Diego, CA, with the highest scoring abstracts in the categories of undergraduate student, medical student, graduate student, resident physician, and postdoctoral fellow.

2 Dec 2011